F

Fate Therapeutics
D

FATE

1.27000
USD
-0.12
(-8.63%)
مغلق
حجم التداول
60,355
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
145,583,938
أصول ذات صلة
A
ARWR
-0.480
(-2.96%)
15.750 USD
C
CRSP
0.050
(0.12%)
41.360 USD
E
EDIT
-0.20500
(-9.45%)
1.96500 USD
N
NTLA
-0.04000
(-0.48%)
8.31000 USD
R
RGEN
-3.770
(-2.87%)
127.530 USD
S
SGMO
-0.02290
(-4.55%)
0.48010 USD
المزيد
الأخبار المقالات

العنوان: Fate Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.